Scribd Logo
Upload

Welcome to Scribd!

  • Summary Pembrolizu Set

    Uploaded by

    Billie Edgara
    4 views1 page
    1. A randomized, placebo-controlled phase 3 study found that pembrolizumab plus chemotherapy led to improved outcomes compared to chemotherapy alone as first-line treatment for advanced esophageal cancer. 2. A phase 3 trial showed that pembrolizumab alone or with chemotherapy led to improved outcomes over chemotherapy alone as first-line treatment for advanced gastric or gastroesophageal junction cancer. 3. Another randomized phase 3 trial demonstrated that pembrolizumab led to improved outcomes compared to paclitaxel as second-line treatment for advanced gastric or gastroesophageal cancer.

    Original Description:

    Copyright

    © © All Rights Reserved

    Available Formats

    TXT, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    1. A randomized, placebo-controlled phase 3 study found that pembrolizumab plus chemotherapy led to improved outcomes compared to chemotherapy alone as first-line treatment for advanced esophageal cancer. 2. A phase 3 trial showed that pembrolizumab alone or with chemotherapy led to improved outcomes over chemotherapy alone as first-line treatment for advanced gastric or gastroesophageal junction cancer. 3. Another randomized phase 3 trial demonstrated that pembrolizumab led to improved outcomes compared to paclitaxel as second-line treatment for advanced gastric or gastroesophageal cancer.

    Copyright:

    © All Rights Reserved
    Download as TXT, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    4 views1 page

    Summary Pembrolizu Set

    Uploaded by

    Billie Edgara
    1. A randomized, placebo-controlled phase 3 study found that pembrolizumab plus chemotherapy led to improved outcomes compared to chemotherapy alone as first-line treatment for advanced esophageal cancer. 2. A phase 3 trial showed that pembrolizumab alone or with chemotherapy led to improved outcomes over chemotherapy alone as first-line treatment for advanced gastric or gastroesophageal junction cancer. 3. Another randomized phase 3 trial demonstrated that pembrolizumab led to improved outcomes compared to paclitaxel as second-line treatment for advanced gastric or gastroesophageal cancer.

    Copyright:

    © All Rights Reserved
    Download as TXT, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 1

    1: Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li

    Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E,
    Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P,
    Kato K; KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus
    chemotherapy alone for first-line treatment of advanced oesophageal cancer
    (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021 Aug
    28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4. Erratum in: Lancet.
    2021 Nov 20;398(10314):1874. PMID: 34454674.

    2: Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I,
    Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N,
    Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A,
    Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and
    Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone
    for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3
    Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. doi:
    10.1001/jamaoncol.2020.3370. PMID: 32880601; PMCID: PMC7489405.

    3: Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro


    L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott
    RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061
    investigators. Pembrolizumab versus paclitaxel for previously treated, advanced
    gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-
    label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392(10142):123-133. doi:
    10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4. PMID: 29880231.

    4: Chung HC, Kang YK, Chen Z, Bai Y, Wan Ishak WZ, Shim BY, Park YL, Koo DH, Lu
    J, Xu J, Chon HJ, Bai LY, Zeng S, Yuan Y, Chen YY, Gu K, Zhong WY, Kuang S, Shih
    CS, Qin SK. Pembrolizumab versus paclitaxel for previously treated advanced
    gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-
    label, phase 3 trial in Asian patients. Cancer. 2022 Mar 1;128(5):995-1003. doi:
    10.1002/cncr.34019. Epub 2021 Dec 8. PMID: 34878659; PMCID: PMC9299889.

    5: Wainberg ZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E, Bang YJ,
    Chung HC, Yamaguchi K, Varga E, Chen JS, Hochhauser D, Thuss-Patience P, Al-
    Batran SE, Garrido M, Kher U, Shih CS, Shah S, Bhagia P, Chao J. Efficacy of
    Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer
    with Programmed Death Ligand 1 Combined Positive Score ≥10. Clin Cancer Res.
    2021 Apr 1;27(7):1923-1931. doi: 10.1158/1078-0432.CCR-20-2980. Epub 2021 Jan
    14. PMID: 33446564.

    6: Van Cutsem E, Amonkar M, Fuchs CS, Alsina M, Özgüroğlu M, Bang YJ, Chung HC,
    Muro K, Goekkurt E, Benson AB 3rd, Sun W, Wainberg ZA, Norquist JM, Chen X, Shih
    CS, Shitara K. Health-related quality of life in advanced
    gastric/gastroesophageal junction cancer with second-line pembrolizumab in
    KEYNOTE-061. Gastric Cancer. 2021 Nov;24(6):1330-1340. doi:
    10.1007/s10120-021-01200-w. Epub 2021 Aug 7. Erratum in: Gastric Cancer. 2021
    Sep 18;: PMID: 34363528; PMCID: PMC8502140.

    You might also like